CytoReason articles

The Challenge:
To understand the molecular effect of a ph-3 drug (Drug A) which showed moderate outcomes and to recommend next steps to increase response rates.

The Challenge:
One of the most common challenges in immuno-oncology is identifying the indications and patient populations that would benefit from a specific therapy, especially on top of Standard of Care (SOC) treatments. Our platform tackled this challenge of indication prioritization and patient stratification for a combination of a specific target (A) with an anti-PDX drug that one of our big pharma clients was considering.

The Challenge:
With a drug in pre-clinical stage, our client was looking for the first indication to go into clinical trials.